For how we live.
A Global Burden of Disease analysis finds the share of female breast-cancer deaths tied to high fasting plasma glucose rose from 1990 to 2023 and is projected to keep rising — but the design cannot prove causation.
The FDA approved PTC Therapeutics' sepiapterin in July 2025. In the phase 3 APHENITY trial, responders saw a 63% fall in blood phenylalanine over six weeks against roughly no change on placebo.
Visceral fat packed around the organs tends to be shed preferentially with modest weight loss. What lingers is subcutaneous fat — and you cannot choose where it comes off, which is what makes the belly feel stubborn.
Short sleep is tied to obesity, and experiments suggest the link is partly causal. Adults told to sleep longer ate about 270 fewer calories a day; dieters who slept less lost far less of their weight as fat.
Standing up every half hour is common desk advice. A meta-analysis of seven trials found brief standing breaks trim post-meal glucose a little, but short light-walking breaks cut both glucose and insulin far more.
Losing weight lowers resting metabolism and keeps it low — Biggest Loser contestants ran hundreds of calories below baseline six years on. But that brake slows loss; it does not store fat.
Insulin resistance usually causes no symptoms you can feel, which is why it is found through blood tests rather than how you seem. The visible clues are subtle — and it rarely travels alone.
Walking pads promise movement without leaving your desk. A trial found walking while working slowed typing but did not harm cognition; a second found hourly walking cut post-meal glucose and blood pressure.
When you eat may shape how you sleep, but the science is young. The clearest signal is that a heavy meal close to bedtime disrupts sleep, while simply shrinking your eating window neither reliably helps nor harms it.
Yes — the hormones released under stress push glucose up, which is why steroids and severe illness cause hyperglycaemia. Whether everyday stress raises long-term diabetes risk is a smaller, murkier effect.
Randomised trials show a Palaeolithic diet trims weight and risk markers in the short term. A two-year trial found the early edge over an ordinary healthy diet had mostly faded — and that people struggled to stick to it.
Prediabetes is a high-risk state, not a diagnosis of diabetes. In the trial that defined the field, lifestyle change cut progression by 58 percent — and returning to normal glucose carried a benefit of its own.
Scans confirmed that adults keep heat-producing brown fat, switched on by cold and linked to better metabolic health. Whether you can build enough of it to matter for weight is far less certain.
Saving starch for the end of a meal reliably blunts the glucose rise afterwards in small trials — but the evidence is short-term, low-certainty, and silent on whether it changes long-term control.
Marketed as a natural weight-loss drug, berberine rests on small, mostly low-quality trials showing modest effects on blood sugar and cholesterol — with no weight-loss evidence to match the hype.
Head-to-head randomised trials find low-carbohydrate and low-fat diets produce similar weight loss over a year or two. The differences that survive are in blood lipids and glycemic control, not the scale.
In 69 people across normal weight, overweight and type 2 diabetes, a stevia drink behaved like water — no shift in glucose, insulin, gut hormones, appetite or how much they ate next.
In-lab trials that restricted sleep on weekdays and allowed recovery at the weekend found insulin sensitivity and glucose tolerance still worsened. Population surveys point the other way, and the designs explain why.
Feeding studies find that when fructose replaces other carbohydrate at equal calories, liver fat barely moves. The liver damage tracks the extra energy, not the sugar's molecular identity.
Pooling 291 participants, researchers found time-restricted eating modestly lowered a liver enzyme and body mass index — but didn't significantly reduce liver fat itself or improve insulin resistance.
The LiverScreen project ran transient elastography across nine countries, then sent everyone who screened positive to a hepatologist. The gap between the two numbers is the interesting part.
A meta-analysis of continuous glucose monitors in people without diabetes found a real effect on blood sugar — but only in those with prediabetes. In healthy users, the evidence for a metabolic benefit was not there.
One proposes a rate-of-change benchmark from 153 non-diabetic wearers. The other put ten young adults through food, exercise and a laboratory stress test to see what actually moves the line.